# Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC

> **NCT02024412** · PHASE3 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** monosialotetrahexosylganglioside Sodium
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT02024412
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024412, "Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02024412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*